Determinants of virological failure among patients on first line highly active antiretroviral therapy (HAART) in Southwest Ethiopia: A case-control study

Background Virological failure remains a public health concern among patients with human immunodeficiency virus (HIV) after treatment initiation. Ethiopia is one of the countries that aims to achieve the global target of 90-90-90 that aims to achieve 90% virological suppression, but there is a paucity of evidence on the determinants of virological failure. Therefore, the study is intended to assess determinants of virological treatment failure among patients on first-line highly active antiretroviral therapy (HAART) at Mizan Tepi University Teaching Hospital (MTUTH), Southwest Ethiopia. Method A hospital-based unmatched case-control study was conducted from 11 November to 23 December 2020, among 146 cases and 146 controls. All cases and controls were selected randomly using computer-generated random numbers based on their medical record numbers. During the document review, data were collected using checklists, entered into Epi-data version 4.0.2, and analyzed by SPSS version 25. A multivariable logistic regression analysis was done to identify the independent determinants of virological treatment failure. Results In this study, being male (adjusted odds ratio (AOR) = 1.89, 95% CI: 1.04, 3.47), substance use (AOR = 2.67, 95% CI: 1.40, 4.95), baseline hemoglobin (Hgb) < 12 mg/dl (AOR = 3.22, 95% CI: 1.82, 5.99), poor drug adherence (AOR = 3.84, 95% CI: 1.77, 5.95), restart ART medication (AOR = 2.45, 95% CI: 1.69, 7.35), and opportunistic infection (OI) while on HAART (AOR = 4.73, 95% CI: 1.76, 12.11) were determinants of virological treatment failure. Conclusion The study revealed that the sex of the patient, history of substance use, baseline Hgb < 12 mg/dl, poor drug adherence, restart after an interruption, and having OI through the follow-up period were determinants of virological failure. Therefore, program implementation should consider gender disparity while men are more prone to virological failure. It is also imperative to implement targeted interventions to improve drug adherence and interruption problems in follow-up care. Moreover, patients with opportunistic infections and restart HAART need special care and attention.

[1]  Animut Alebel,et al.  Magnitude and associated factors of virological failure among children on ART in Bahir Dar Town public health facilities, Northwest Ethiopia: a facility based cross-sectional study , 2021, Italian Journal of Pediatrics.

[2]  B. Derseh,et al.  Virological Treatment Failure Among Adult HIV/AIDS Patients from Selected Hospitals of North Shoa Zone, Amhara Region, Ethiopia , 2020, Infection and drug resistance.

[3]  Niguss Cherie,et al.  Determinants of Virologic Failure Among Adults on Second Line Antiretroviral Therapy in Wollo, Amhara Regional State, Northeast Ethiopia , 2020, HIV/AIDS.

[4]  Z. Mekonnen,et al.  A Facility-Based Cross-Sectional Study on the Implementation of the IMNCI Program in Public Health Centers of Soro District, Hadiya Zone, Southern Ethiopia , 2020, Pediatric health, medicine and therapeutics.

[5]  Ravindra K. Gupta,et al.  Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi: an observational cohort study , 2020, The lancet. HIV.

[6]  Kebadnew Mulatu,et al.  Determinants of virological failure among adults on first-line highly active antiretroviral therapy at public health facilities in Kombolcha town, Northeast, Ethiopia: a case–control study , 2020, BMJ Open.

[7]  D. Geremew,et al.  HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis , 2019, BMC Public Health.

[8]  Abiot Girma,et al.  Predictors of Clinical and Immunological Failure Among Patients on First-Line Antiretroviral Therapy (ART) in Southwest Ethiopia , 2019, HIV/AIDS.

[9]  Esayas Kebede Gudina,et al.  Determinants of First-line Antiretroviral Treatment Failure Among Patients on Antiretroviral Therapy in Public Hospitals Jimma, Southwest Ethiopia a Case-Control Study , 2019, Rehabilitation Science.

[10]  N. Dereje,et al.  Prevalence And Predictors Of Opportunistic Infections Among HIV Positive Adults On Antiretroviral Therapy (On-ART) Versus Pre-ART In Addis Ababa, Ethiopia: A Comparative Cross-Sectional Study , 2019, HIV/AIDS.

[11]  Habtemu Jarso,et al.  Predictors of virological treatment failure among adult HIV patients on first-line antiretroviral therapy in Woldia and Dessie hospitals, Northeast Ethiopia: a case-control study , 2019, BMC Infectious Diseases.

[12]  J. Routy,et al.  Clinical outcome after lipectomy in the management of patients with human immunodeficiency virus-associated dorsocervical fat accumulation , 2019, Medicine.

[13]  J. Boncy,et al.  Virologic outcome among patients receiving antiretroviral therapy at five hospitals in Haiti , 2018, PloS one.

[14]  Amare Tariku,et al.  Determinants of virological failure among patients on highly active antiretroviral therapy in University of Gondar Referral Hospital, Northwest Ethiopia: a case–control study , 2017, HIV/AIDS.

[15]  Nuredin Nassir Azmach.  Adherence to Antiretroviral Therapy and Associated Factors Among Adult ARV Users in Arba Minch Hospital, Southern Ethiopia , 2017 .

[16]  R. Wanyenze,et al.  Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014–July 2015 , 2017, BMC Infectious Diseases.

[17]  K. Yirdaw,et al.  Patients who restart antiretroviral medication after interruption remain at high risk of unfavorable outcomes in Ethiopia , 2017, BMC Health Services Research.

[18]  D. Colby,et al.  Cigarette smoking is associated with high HIV viral load among adults presenting for antiretroviral therapy in Vietnam , 2017, PloS one.

[19]  R. Redfield,et al.  Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda , 2016, Tropical medicine & international health : TM & IH.

[20]  S. Han,et al.  Opportunistic diseases among HIV-infected patients: a multicenter-nationwide Korean HIV/AIDS cohort study, 2006 to 2013 , 2016, The Korean journal of internal medicine.

[21]  A. King,et al.  Predictors of antiretroviral therapy failure in an urban HIV/AIDS clinic in Addis Ababa, Ethiopia , 2016 .

[22]  R. Paredes,et al.  Determinants of virological failure and antiretroviral drug resistance in Mozambique. , 2015, The Journal of antimicrobial chemotherapy.

[23]  B. Musa,et al.  Incidence of tuberculosis and immunological profile of TB/HIV co-infected patients in Nigeria , 2015, Annals of thoracic medicine.

[24]  R. Kosgei,et al.  Factors Associated with Virological Failure and Suppression after Enhanced Adherence Counselling, in Children, Adolescents and Adults on Antiretroviral Therapy for HIV in Swaziland , 2015, PloS one.

[25]  B. Gelaw,et al.  The effect of incident tuberculosis on immunological response of HIV patients on highly active anti-retroviral therapy at the university of Gondar hospital, northwest Ethiopia: a retrospective follow-up study , 2014, BMC Infectious Diseases.

[26]  K. Tufon,et al.  Immuno-haematologic and virologic responses and predictors of virologic failure in HIV-1 infected adults on first-line antiretroviral therapy in Cameroon , 2014, Infectious Diseases of Poverty.

[27]  T. F. Rinke de Wit,et al.  HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study , 2014, AIDS Research and Therapy.

[28]  R. Hogg,et al.  Gender Differences in Clinical Outcomes among HIV-Positive Individuals on Antiretroviral Therapy in Canada: A Multisite Cohort Study , 2013, PloS one.

[29]  Tania B. Huedo-Medina,et al.  Sex differences in adherence to highly active antiretroviral therapy: A meta-analysis , 2012, AIDS care.

[30]  S. Delany-Moretlwe,et al.  Risk factors for discordant immune response among HIV-infected patients initiating antiretroviral therapy: A retrospective cohort study , 2012 .

[31]  F. Schmidt.  Meta-Analysis , 2008 .

[32]  J. Carton,et al.  Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART , 2007, AIDS.

[33]  N. Imami,et al.  Immunological and virological consequences of patient‐directed antiretroviral therapy interruption during chronic HIV‐1 infection , 2005, Clinical and experimental immunology.

[34]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[35]  J. Slim,et al.  Women have a greater immunological response to effective virological HIV-1 therapy. , 2003, AIDS.